Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nuzyra (omadacycline) is a USFDA approved novel antibiotic for the treatment of community-acquired bacterial pneumonia. Now it is being evaluated for the treatment of post-exposure prophylaxis of inhalational anthrax.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
The proceeds from the acquisition will advance the commercialization of Nuzyra (omadacycline), a tetracycline antibiotic, indicated for the treatment of adult patients with community-acquired bacterial pneumonia, and support the development of additional therapies.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $462.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 21, 2023
Details:
The agreement aims to support the development of omadacycline for post-exposure prophylaxis and pulmonary anthrax and the US-based commercial manufacturing of Nuzyra, a novel once-daily antibiotic approved for the treatment of community-acquired bacterial pneumonia and ABSSSI.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $304.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2023
Details:
Nuzyra (omadacycline tosylate) is a novel antibiotic which binds to the 30S ribosomal subunit and blocks protein synthesis and is available for the treatment of of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
The proceeds from the acquisition will advance the commercialization of Nuzyra (omadacycline), a tetracycline antibiotic, indicated for the treatment of adult patients with community-acquired bacterial pneumonia, and support the development of additional therapies.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $287.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2023
Details:
Nuzyra (omadacycline tosylate) is a novel antibiotic which binds to the 30S ribosomal subunit and blocks protein synthesis, available for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $304.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 05, 2023
Details:
NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Under the terms of the agreement, BARDA will award initial funding for the development of NUZYRA (omadacycline tosylate) for the treatment of pulmonary anthrax and the purchase of an initial 2,500 treatment courses of NUZYRA to add to the current SNS.
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $284.0 million Upfront Cash: Undisclosed
Deal Type: Partnership October 31, 2022
Details:
NUZYRA ® (omadacycline tosylate) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Lead Product(s): Omadacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuzyra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022